Dr Reddy’s announce launch of Bortezomib for injection, 3.5 mg single-dose vial in US
Bortezomib for injection is a proteasome inhibitor indicated for the treatment of adult patients with multiple myeloma and mantle…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
multiple myeloma
NATCO gets US FDA approval for Pomalidomide capsules
It is indicated for the treatment of multiple myeloma
US FDA grants orphan drug designation to oNKord from Glycostem for multiple myeloma
The designation will provide Glycostem with eligibility for seven years of market exclusivity and clear FDA guidance on specific…
SpringWorks Therapeutics in pact with Janssen to assess Nirogacestat with Teclistamab in patients…
Third collaboration to evaluate nirogacestat in combination with BCMA therapies across modalities
Zydus Cadila gets US FDA approval for Doxorubicin Hydrochloride Liposome Injection
Liposomal doxorubicin is a chemotherapeutic agent that is used alone or with other treatments/medications to treat certain types…
GSK gets USFDA approval for BLENREP to treat relapsed or refractory multiple myeloma
BLENREP is the fifth major medicine approval for GSK in 2020
Glenmark receives Orphan Drug Designation for GBR 1342
The drug is indicated for the treatment of multiple myeloma Glenmark Pharmaceuticals (Glenmark), announced that the US Food and…
Global multiple myeloma treatment market value to approach $9 billion by 2021: GBI Research
This will be driven primarily by rising multiple myeloma prevalence as a result of an aging population The global multiple…